Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Oncoimmunology
|
September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Tian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Cancer
|
July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J Motzer, Bernard Escudier, Saby George, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Oncoimmunology
|
September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Tian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Cancer
|
July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J Motzer, Bernard Escudier, Saby George, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Page
of 10